Dr. Frederico Severino Martins joins esqLABS

 

 From May 18, 2020 on Dr. Frederico Martins, a trained Pharmacist from University University of São Paulo, will be reinforcing esqLABS.

 

WE WELCOME FREDERICO TO THE TEAM!

Dr. Frederico Martins joins esqLABS

Dr. Frederico Martins is pharmacist with a PhD in Pharmaceutical Sciences from the University of São Paulo, Brazil. Prior to joining esqLABS, Dr. Martins worked as a pharmacometrics leader at Galapagos Pharmaceuticals in Paris, France, and Certara’s SimCYP division in Sheffield, England.

At Galapagos he was responsible for implementation and application of PBPK models to guide drug development and translational strategies. He contributed to key decisions for oral drugs entering the clinical stage, formulation development, drug-drug interaction, late stage development, as well as translational evaluation of drugs for rare diseases. During his time working at Certara, Dr. Martins was deeply involved with the development and qualification of Simcyp dermal platform, and training courses. He has hands-on experience in IVIVE, IVIVC, first-in-human dose selection and application of PBPK in formulation development.  

His primary focus area at the moment is anti-inflammatory, pulmonary fibrosis, immunology and skin diseases.  Since 2019, Dr. Martins is a visiting professor at State University of Maringá, Brazil, collaborating with the post-graduate program in pharmaceutical science as graduate students’ co-supervisor.

Peer Reviewed Journal Articles

  • Martins FS, Sy SKB, Fonseca MJV, de Freitas O. Pharmacokinetics, Pharmacodynamics and Dermal Distribution of 5-Methoxypsoralen Based on a Physiologically Based Pharmacokinetic Model to Support Phytotherapy Using Brosimum gaudichaudii. Planta Med 2020; 86: 276–283
  • Biesdorf C, Martins FS, Sy SKB, Diniz A. Physiologically-based pharmacokinetics of ziprasidone in pregnant women. Br J Clin Pharmacol 2019; 85: 914–923
  • Ivan ALM, Campanini MZ, Martinez RM, Ferreira VS, Steffen VS, Vicentini FT, Vilela FM, Martins FS, Zarpelon AC, Cunha TM. Pyrrolidine dithiocarbamate inhibits UVB-induced skin inflammation and oxidative stress in hairless mice and exhibits antioxidant activity in vitro. J Photochem Photobiol B Biol 2014; 138: 124–133
  • Borges LL, Martins FS, Conceição EC, Silveira D. Optimization of the Spray‐Drying Process for Developing Jabuticaba Waste Powder Employing Response Surface Methodology. J Food Process Eng 2017; 40: e12276
  • Martins FS, Borges LL, Ribeiro CSC, Reifschneider FJB, Conceição EC. Novel approaches to extraction methods in recovery of capsaicin from habanero pepper (CNPH 15.192). Pharmacogn Mag 2017; 13: S375
  • de Morais Rodrigues MC, Borges LL, Martins FS, Mourão RH V, da Conceição EC. Optimization of ultrasound-assisted extraction of phenolic compounds from Myrcia amazonica(Myrtaceae) leaves. Pharmacogn Mag 2016; 12: 9
  • Silva Filho OP, Oliveira LAR, Martins FS, Borges LL, De Freitas O, da Conceição EC. Obtainment of pellets using the standardized liquid extract of Brosimum gaudichaudii Trécul (Moraceae). Pharmacogn Mag 2015; 11: 170
  • Da Mota MF, Benfica PL, Batista AC, Martins FS, de Paula JR, Valadares MC. Investigation of Ehrlich ascites tumor cell death mechanisms induced by Synadenium umbellatum J Ethnopharmacol 2012; 139: 319–329
  • Silva EM da, Freitas SL, Martins FS, Couto RO, Pinto MV, Paula JR de, Conceição EC da, Bara MTF. Isolation and quantitative HPLC-PDA analysis of lupeol in phytopharmaceutical intermediate products from Vernonanthura ferruginea (Less.) H. Rob. 2012;

Conference Posters

  • Martins FS , Krache A, Helmer E, Namour F, Taneja A. Application of Physiologically Based Pharmacokinetic (PBPK) Modelling to Support First in Human dose selection. Population Approach Group Europe, 2019, Stockholm, Sweden
  • Biesdorf C, Martins FS, Diniz A. Physiologically-based pharmacokinetic modeling of ziprasidone in pregnant women. In: Journal Of Pharmacokinetics And Pharmacodynamics. Springer/Plenum Publishers 233 Spring St, New York, Ny 10013 Usa, 2018: S12–S13
  • Martins FS, Patel N, Jamei M ,Polak S. Mechanistic Physiologically-Based Pharmacokinetic Modelling for Prediction of Dermal Absorption in Psoriatic Patients. Perspective in Percutaneous Penetration, 2018, La Grande Motte, France.
  • Patel N, Martins FS, Jamei M, Ghosh P, Raney S.G,Zhang X, Tsakalozou E, Polak S. Integration of physicochemical product characteristics within a mechanistic dermal PBPK model to support virtual bioequivalence evaluation of topical drug products: A case study with acyclovir topical creams. American Association of Pharmaceutical Scientists, 2017 San Diego, USA.
  • Martins FS, Patel N, Clarke J, Polak   Multi-phase Multi-layer Mechanistic Physiologically-based Pharmacokinetic Dermal Absorption Model Verification Including Inter- and Intra-individual Variability Assessment Using Nicotine as a Model Drug. American Association of Pharmaceutical Scientists PharmaSci, 2018, Washington, USA.
  • Martins FS, Patel N, Jamei M, Polak S. Development and Validation of a Dermal PBPK Model for Prediction of the Hair Follicular Absorption of Caffeine: Application of the Simcyp MPML MechDermA model , 2017, 14TH ISSX, Cologne, Germany.
  • Martins FS, Patel N, Jamei M, Polak S.Development and validation of Dermal PBPK model towards virtual bioequivalence assessment: Prediction of dermal drug absorption of various Ibuprofen formulations using Simcyp MechDermA model, American Association of Pharmaceutical Scientists PharmaSci, 2018, Washington, USA.
  • Martins FS, Patel N, Salem F, Jamei M, Polak S. Multi-phase Multi-layer MechDermA model. Development, verification and application of a PBPK-PD model of dermal absorption for transdermal product assessment, 2016, Drug Metabolism and Disposition Group, Paris, France.

S. Food and Drug Administration grant

Development and validation of dermal PBPK modelling platform towards virtual bioequivalence assessment considering population variability. 2016-2019.

FDA Grant #: 1U01FD005225-01

 

Get in touch now

Contact

esqLABS GmbH | Hambierich 34 | 26683 Saterland | Germany
Tel. +49 151 / 58559070 | info@esqLABS.com